In:
Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 100, No. 20 ( 2021-05-21), p. e25749-
Abstract:
Thymosin alpha-1 (Tα1) is an immunomodulatory and antiviral agent with potential effects on chronic hepatitis B and liver cancer. Its impact on solitary hepatocellular carcinoma (HCC) remains controversial, so we aimed to investigate the efficacy of Tα1 in solitary HBV-related HCC patients after curative resection. Between May 2010 and April 2016, 468 patients with solitary HBV-related HCC after curative resection were analyzed. Propensity score matching (PSM) was used to minimize confounding variables. Risk factors were identified by the Cox proportional hazards model. Recurrence-free survival (RFS) rates, overall survival (OS) rates, immunological, and virologic response were compared. The median follow up was 60.0 months. Immunological response improved in the Tα1 group compared with the control group ( P 〈 .001) but the virologic response was similar between 2 groups after 24 months. Patients with Tα1 therapy had better RFS and OS before ( P = .018 and P 〈 .001) and after ( P = .006 and P 〈 .001) propensity matching. Multivariate analysis revealed that Tα1 therapy was an independent prognostic factor for both OS ( P 〈 .001, HR = 0.308, 95% CI: 0.175–0.541) and RFS ( P 〈 .001, HR = 0.381, 95% CI: 0.229–0.633). Tα1 as an adjuvant therapy improves the prognosis of solitary HBV-related HCC patients after curative liver resection.
Type of Medium:
Online Resource
ISSN:
0025-7974
,
1536-5964
DOI:
10.1097/MD.0000000000025749
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
2049818-4
